Injection of fibrin sealant using reconstituted components in spinal applications
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61B-017/56
A61L-027/54
A61B-017/00
A61K-038/36
A61K-038/48
A61K-045/06
A61L-024/10
A61L-027/22
A61L-027/50
출원번호
US-0533450
(2012-06-26)
등록번호
US-8986304
(2015-03-24)
발명자
/ 주소
Burkinshaw, Brian D.
Whitlock, Steven I.
Pauza, Kevin
Richards, Mark I.
Rogan, James B.
출원인 / 주소
BSNC Holding, LLC
대리인 / 주소
Clearpat Services, LLC
인용정보
피인용 횟수 :
0인용 특허 :
123
초록▼
A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus. The method includes injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises fibrinog
A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus. The method includes injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises fibrinogen and an activating compound, wherein at least a portion of the fibrin forms after injection, wherein the fibrinogen, the activating compound or both has been reconstituted with a solution containing at least one additive, with the proviso that a corticosteroid is absent from the fibrin sealant injected into the disc.
대표청구항▼
1. A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus, comprising: injecting a fibrin sealant into the disc, wherein neither the nucleus pulposus nor the annulus fibrosus has been heated, to reduce at least a portion of the at least one d
1. A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus, comprising: injecting a fibrin sealant into the disc, wherein neither the nucleus pulposus nor the annulus fibrosus has been heated, to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises fibrinogen and an activating compound, wherein at least a portion of the fibrin forms after injection, wherein the fibrinogen, the activating compound or both has been reconstituted with a solution containing at least one additive, wherein a corticosteroid is absent from the fibrin sealant injected into the disc, and wherein the injecting occurs by inserting an introducer needle having a tip into an intra-discal space, inserting a second needle or a polymeric catheter through the introducer needle up to but not beyond the tip of the introducer needle, and injecting the fibrinogen through the introducer needle and injecting the activating compound through the second needle or polymeric catheter, or injecting the activating compound through the introducer needle and injecting the fibrinogen through the second needle or polymeric catheter. 2. The method of claim 1, wherein the fibrin sealant consists essentially of fibrinogen, the activating compound and the at least one additive, and optionally calcium chloride. 3. The method of claim 1, wherein the fibrin sealant consists of fibrinogen, the activating compound, and the at least one additive, and optionally containing calcium chloride. 4. The method of claim 1, wherein the fibrin sealant further comprises calcium chloride which is injected with either the fibrinogen, the activating compound, or both. 5. The method of claim 1, wherein the activating compound is thrombin. 6. The method of claim 1, wherein the method consists of the injecting step. 7. The method of claim 1, the additive is selected from the group consisting of antibiotics; antiproliferative, cytotoxic, and antitumor drugs including analgesic; antiangiogen; antibody; antivirals; cytokines; colony stimulating factors; proteins; chemoattractants; EDTA; histamine; antihistamine; erythropoietin; antifungals; antiparasitic agents; non-corticosteroid anti-inflammatory agents; anticoagulants; anesthetics; analgesics; oncology agents; cardiovascular drugs; glycoproteins; fibronectin; peptides; interferons; cartilage inducing factors; protease inhibitors; vasoconstrictors, vasodilators, demineralized bone or bone morphogenetic proteins; hormones; lipids; carbohydrates; proteoglycans; antiangiogenins; antigens; DBM; hyaluronic acid and salts and derivatives thereof; polysaccharides; cellulose compounds and derivatives thereof; gene therapy reagents; genetically altered cells, stem cells including mesenchymal stem cells with transforming growth factor, and/or other cells; cell growth factors; type I collagen; elastin; sulfated glycosaminoglycan (sGAG), glucosamine sulfate; pH modifiers; methylsulfonylmethane (MSM); osteogenic compounds; osteoconductive compounds; plasminogen; nucleotides; oligonucleotides; polynucleotides; polymers; osteogenic protein 1 (0P-1 including recombinant OP-1); LMP-1 (Lim Mineralization Protein-1); cartilage; oxygen-containing components; enzymes; melatonin; vitamins; and nutrients. 8. The method of claim 1, wherein at least one additive is a local anesthetic. 9. The method of claim 1, wherein no portion of the nucleus pulposus has been removed by surgery. 10. The method of claim 1, wherein the at least one defect is a tear or fissure in the annulus fibrosus. 11. The method of claim 1, wherein normal hydrostatic pressure in the disc is restored or normal disc height is restored or both. 12. The method of claim 1, wherein the fibrinogen is autologous. 13. The method of claim 1, wherein the activating compound is thrombin, and wherein a mixture of the fibrinogen and the thrombin is injected. 14. The method of claim 1, wherein the activating compound is thrombin, and wherein the fibrinogen and the thrombin are injected sequentially and at least partially mix in the disc. 15. The method of claim 1, wherein the additives are injected sequentially either before with or after the fibrinogen and the activating compound and at least partially mix in the disc. 16. The method of claim 1, wherein the disc is injected with the fibrin sealant at multiple points. 17. The method of claim 1, wherein the disc is a lumbar disc. 18. The method of claim 1, wherein the disc is a cervical disc. 19. The method of claim 1, wherein the disc is a thoracic disc. 20. The method of claim 1, wherein a contrast agent is injected either before the fibrin sealant, with the fibrin sealant, or after the fibrin sealant has been injected. 21. A method of treating a human back, comprising injecting a fibrin sealant into the nucleus pulposus of a disc, wherein neither a nucleus pulposus nor an annulus fibrosus has been previously heated, to seal at least one defect of the annulus fibrosus, wherein the fibrin sealant comprises fibrinogen and thrombin, wherein the fibrinogen and thrombin forms at least a portion of the fibrin after injection, wherein the fibrinogen, the thrombin or both has been reconstituted with a solution containing at least one additive, wherein the fibrin sealant does not include a corticosteroid, and wherein normal hydrostatic pressure in the disc is restored or normal disc height is restored or both. 22. The method of claim 21, wherein the fibrin sealant consists essentially of fibrinogen, thrombin and the at least one additive. 23. The method of claim 21, wherein the fibrin sealant consists of fibrinogen, thrombin, the at least one additive, and calcium chloride. 24. The method of claim 21, wherein the fibrin sealant further comprises calcium chloride which is injected with either the fibrinogen, the thrombin, or both. 25. The method of claim 21, wherein the method consists of the injecting step. 26. The method of claim 21, wherein the additive is selected from the group consisting of antibiotics; antiproliferative, cytotoxic, and antitumor drugs including; analgesic; antiangiogen; antibody; antivirals; cytokines; colony stimulating factors; proteins; chemoattractants; EDTA; histamine; antihistamine; erythropoietin; antifungals; antiparasitic agents; non-corticosteroid anti-inflammatory agents; anticoagulants; anesthetics; analgesics; oncology agents; cardiovascular drugs; glycoproteins; fibronectin; peptides; interferons; cartilage inducing factors; protease inhibitors; vasoconstrictors, vasodilators, demineralized bone or bone morphogenetic proteins; hormones; lipids; carbohydrates; proteoglycans; antiangiogenins; antigens; DBM; hyaluronic acid and salts and derivatives thereof; polysaccharides; cellulose compounds and derivatives thereof; gene therapy reagents; genetically altered cells, stem cells including mesenchymal stem cells with transforming growth factor, and/or other cells; cell growth factors; type I collagen; elastin; sulfated glycosaminoglycan (sGAG), glucosamine sulfate; pH modifiers; methylsulfonylmethane (MSM); osteogenic compounds; osteoconductive compounds; plasminogen; nucleotides; oligonucleotides; polynucleotides; polymers; osteogenic protein 1 (0P-1 including recombinant OP-1); LMP-1 (Lim Mineralization Protein-1); cartilage; oxygen-containing components; enzymes; melatonin; vitamins; and nutrients. 27. The method of claim 21, wherein at least one additive is a local anesthetic. 28. The method of claim 21, wherein no portion of the nucleus pulposus has been removed by surgery. 29. The method of claim 21, wherein the at least one defect is a tear or fissure in the annulus fibrosus. 30. The method of claim 21, wherein the fibrinogen is autologous. 31. The method of claim 21, wherein a mixture of the fibrinogen and thrombin is injected. 32. The method of claim 21, wherein the fibrinogen and thrombin are injected sequentially and at least partially mix in the disc. 33. The method of claim 21, wherein the disc is injected with the fibrin sealant at multiple positions in the disc. 34. The method of claim 21, wherein the injecting occurs by inserting an introducer needle having a tip into the nucleus pulposus, inserting a second needle or a polymeric catheter through the introducer needle up to but not beyond the tip of the introducer needle, and injecting the fibrinogen through the introducer needle and injecting the thrombin through the second needle or polymeric catheter, or injecting the thrombin through the introducer needle and injecting the fibrinogen through the second needle or polymeric catheter. 35. The method of claim 21, wherein the disc is a lumbar disc. 36. The method of claim 21, wherein the disc is a cervical disc. 37. The method of claim 21, wherein the disc is a thoracic disc. 38. The method of claim 21, wherein a contrast agent is injected either before the fibrin sealant, with the fibrin sealant, or after the fibrin sealant has been injected. 39. The method of claim 21, wherein the additives are injected sequentially either before with or after the fibrinogen and thrombin and at least partially mix in the disc. 40. A method of treating a human back, comprising providing a mixture of fibrinogen and thrombin within a human disc to treat at least one defect of an annulus fibrosus wherein neither a nucleus pulposus nor the annulus fibrosus has been heated, and wherein the fibrinogen, the thrombin or both has been reconstituted with a solution containing at least one additive, and wherein a corticosteroid is absent from the mixture, and wherein the injecting occurs by inserting an introducer needle having a tip into an intra-discal space, inserting a second needle or a polymeric catheter through the introducer needle up to but not beyond the tip of the introducer needle, and injecting the fibrinogen through the introducer needle and injecting the thrombin through the second needle or polymeric catheter, or injecting the thrombin through the introducer needle and injecting the fibrinogen through the second needle or polymeric catheter. 41. The method of claim 40, wherein the fibrin sealant consists essentially of fibrinogen, thrombin and the at least one additive. 42. The method of claim 40, wherein the fibrin sealant consists of fibrinogen, thrombin, the at least one additive, and calcium chloride. 43. The method of claim 40, wherein calcium chloride is provided with either the fibrinogen, the thrombin, or both. 44. The method of claim 40, wherein the additive is selected from the group consisting of antibiotics; antiproliferative, cytotoxic, and antitumor drugs; analgesic; antiangiogen; antibody; antivirals; cytokines; colony stimulating factors; proteins; chemoattractants; EDTA; histamine; antihistamine; erythropoietin; antifungals; antiparasitic agents; non-corticosteroid anti-inflammatory agents; anticoagulants; anesthetics; analgesics; oncology agents; cardiovascular drugs; glycoproteins; fibronectin; peptides; interferons; cartilage inducing factors; protease inhibitors; vasoconstrictors, vasodilators, demineralized bone or bone morphogenetic proteins; hormones; lipids; carbohydrates; proteoglycans; antiangiogenins; antigens; DBM; hyaluronic acid and salts and derivatives thereof; polysaccharides; cellulose compounds and derivatives thereof; gene therapy reagents; genetically altered cells, stem cells including mesenchymal stem cells with transforming growth factor, and/or other cells; cell growth factors; type I collagen; elastin; sulfated glycosaminoglycan (sGAG), glucosamine sulfate; pH modifiers; methylsulfonylmethane (MSM); osteogenic compounds; osteoconductive compounds; plasminogen; nucleotides; oligonucleotides; polynucleotides; polymers; osteogenic protein 1 (0P-1 including recombinant OP-1); LMP-1 (Lim Mineralization Protein-1); cartilage; oxygen-containing components; enzymes; melatonin; vitamins; and nutrients. 45. The method of claim 40, wherein no portion of the nucleus pulposus has been removed by surgery. 46. The method of claim 40, wherein the at least one defect is a tear or fissure in the annulus fibrosus. 47. The method of claim 40, wherein normal hydrostatic pressure in the disc is restored or normal disc height is restored or both. 48. The method of claim 40, wherein the fibrinogen is autologous. 49. The method of claim 40, wherein a mixture of fibrinogen, thrombin and the at least one additive is provided. 50. The method of claim 40, wherein the fibrinogen and thrombin are provided sequentially and at least partially mix in the disc. 51. The method of claim 40, wherein the disc is provided with the fibrin sealant at multiple positions in the disc. 52. The method of claim 40, wherein the disc is a lumbar disc. 53. The method of claim 40, wherein the disc is a cervical disc. 54. The method of claim 40, wherein the disc is a thoracic disc. 55. The method of claim 40, wherein a contrast agent is provided either before the fibrin sealant, with the fibrin sealant, or after the fibrin sealant has been injected. 56. The method of claim 40, wherein the additives are provided sequentially either before with or after the fibrinogen and thrombin and at least partially mix in the disc. 57. The method of claim 21, wherein the injecting occurs by inserting an introducer needle having a tip into the nucleus pulposus, inserting a second needle having a tip into the nucleus pulposus, and injecting the fibrinogen through the introducer needle and injecting the thrombin through the second needle, or injecting the thrombin through the introducer needle and injecting the fibrinogen through the second needle. 58. The method of claim 57, wherein a contrast agent is injected either before the fibrinogen, with the fibrinogen, or after the fibrinogen has been injected, or alternatively before the thrombin, with the thrombin, or after the thrombin has been injected. 59. The method of claim 57, wherein calcium chloride is injected with either the fibrinogen, the thrombin, or both. 60. The method of claim 57, wherein the additives are injected sequentially, either before, with or after the fibrinogen and thrombin and at least partially mix in the disc. 61. The method of claim 40, wherein at least one additive is a local anesthetic.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (123)
Blomback, Birger; Hessel, Birgit; Olsson, Per; Stromberg, Lennart; Swedenborg, Jesper; Stocker, Kurt, Adhesive for the gluing of biological tissues.
Drohan William N. ; MacPhee Martin J. ; Miekka Shirley I. ; Singh Manish S. ; Elson Clive,CAX ; Taylor ; Jr. John R., Chitin hydrogels, methods of their production and use.
Prior Jeffrey J. ; Wallace Donald G. ; Sierra David H. ; DeLustro Frank A., Compositions containing thrombin and microfibrillar collagen and methods for preparation and use thereof.
Herb Armin (Peissenberg DEX) Leibhard Erich (Munich DEX) Gruenewald Heinz (Munich DEX), Device for dispensing measured amounts of multi-component materials.
Brown Ross G. (Terre Haute IN) Bright David R. (Terre Haute IN) Williams Robert D. (Terre Haute IN), Fibrin binder/carrier for active biochemical agents.
Yves Delmotte BE; Arnold Bilstad ; David Amrani ; James DiOrio ; Atif M. Yardimci ; David W. Pennington ; James S. Slepicka ; Cristina Stadler, Fibrin delivery device and method for forming fibrin on a surface.
Edwardson Peter A. D.,GBX ; Fairbrother John E.,GBX ; Gardner Ronald S.,GBX ; Hollingsbee Derek A.,GBX ; Cederholm-Williams Stewart A.,GBX, Fibrin sealant compositions and methods for utilizing same.
Rasmussen Jack D. (77 E. 7th St. Upland CA 91786) Fujitaki Roy K. (721 E. Mendocino St. Altadena CA 91001), Instrument and method for making dental impressions.
Cauthen, III, Joseph C.; Burns, Matthew M.; Wales, Lawrence W.; Dukart, Brian L.; Wessman, Bradley J.; Houfburg, Rodney L.; Bentley, Ishmael, Method and apparatus for the treatment of the intervertebral disc annulus.
Burgess, Willson H.; Greisler, Howard P.; Drohan, William N.; Maciag, Thomas; MacPhee, Martin J., Method of preparing a tissue sealant-treated biomedical material.
Edwardson Peter A. D.,GBX ; Fairbrother John E.,GBX ; Gardner Ronald S.,GBX ; Hollingsbee Derek A.,GBX ; Cederholm-Williams Stewart A.,GBX, Methods and compositions using fibrin monomer to make a fibrin sealant.
Miekka Shirley I. ; Drohan William N. ; Jameson Thomas R. ; Singh Manish P. ; Taylor ; Jr. John R. ; MacPhee Martin J., Methods of production and use of liquid formulations of plasma proteins.
Miekka Shirley I. ; Drohan William N. ; Jameson Thomas R. ; Taylor ; Jr. John R. ; Singh Manish S., Methods of production and use of liquid formulations of plasma proteins.
Miekka, Shirley I.; Drohan, William N.; Jameson, Thomas R.; Taylor, Jr., John R.; Singh, Manish P.; MacPhee, Martin J., Methods of production and use of liquid formulations of plasma proteins.
Antanavich Richard D. (Paso Robles CA) Dorian Randel (Orinda CA), Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant.
Amarpreet S. Sawhney ; David A. Melanson ; Chandrashekar P. Pathak ; Jeffrey A. Hubbell ; Luis Z. Avila ; Mark T. Kieras ; Stephen D. Goodrich ; Shikha P. Barman ; Arthur J. Coury ; Ronald S, Redox and photoinitiator systems for priming for improved adherence of gels to substrates.
Hegasy Ahmed (Leverkusen DEX) Ramsch Klaus-Dieter (Heerlen NLX), Solid medicament formulations containing nifedipine, and processes for their preparation.
MacPhee Martin James ; Drohan William Nash ; Liau Gene ; Haudenschild Christian, Supplemented and unsupplemented tissue sealants, method of their production and use.
MacPhee Martin James ; Drohan William Nash ; Lasa ; Jr. Carlos I.,PHX ; Liau Gene ; Haudenschild Christian, Supplemented and unsupplemented tissue sealants, methods of their production and use.
MacPhee Martin James ; Drohan William Nash ; Woolverton Christoper J., Supplemented and unsupplemented tissue sealants, methods of their production and use.
Taylor Steven R. (Salt Lake City UT) Lampropoulos Fred P. (Salt Lake City UT) Stout Thomas D. (Sandy UT) Smith A. Tony (Salt Lake City UT), Syringe apparatus with attached pressure gauge and timer.
Wadstrom Jonas (Dag Hammarskjolds vag 281 S-756 52 Uppsala SEX), Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer.
Luck Edward E. (Menlo Park CA) Brown Dennis M. (Menlo Park CA), Treatments employing drug-containing matrices for introduction into cellular lesion areas.
Luck Edward E. (Menlo Park CA) Brown Dennis M. (Menlo Park CA), Treatments employing drug-containing matrices for introduction into cellular lesion areas.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.